CurifyLabs Secures $14M Series A Funding to Innovate Personalized Medicine Delivery

CurifyLabs Raises $14 Million to Transform Personalized Medicine

CurifyLabs, a pioneer in health technology, has successfully closed a $14 million Series A funding round aimed at revolutionizing the creation of personalized medicines. This round saw participation from prominent investment firms, including Sandwater and HealthCap, along with Finnish Industry Investment Ltd., Tesi, and existing investors such as Lifeline Ventures. Notably, U.S. customers and employees also joined in the funding effort.

The raised funds will be utilized to amplify CurifyLabs' U.S. operations, enhance supply chain structures, and improve customer support in order to facilitate a more robust product innovation pipeline. CurifyLabs is known for its groundbreaking Compounding System Solution (CSS), which integrates proprietary software, good manufacturing practice (GMP) compliant excipient bases, and cutting-edge 3D printing technology. This innovative system is designed to automate the preparation of personalized medications, ensuring precision and rapidity that far exceeds traditional manual pharmacy processes.

Currently, CurifyLabs' technology is being employed in pharmacies across 21 states in the U.S. and various locations in Europe, compounding and dispensing thousands of custom doses each day. With scaling operations in focus, the company is poised to strengthen its supply chain to guarantee that its growing network of pharmacy partners has reliable access to necessary resources.

Morten E. Iversen, a partner at Sandwater, remarked on the significance of personalized medicine, stating, "It is one of the most crucial emerging fields in healthcare, promoting better patient outcomes and demonstrating solid growth. We aim to empower more pharmacies in delivering personalized medicine efficiently and safely.” He further praised CurifyLabs, emphasizing their unique blend of clinical rigor and operational efficiency that busy pharmacy teams can depend on.

Daniel Karsberg, a partner at HealthCap, added insights from their extensive experience in the life sciences arena, highlighting that exceptional founders excel by marrying scientific depth with pragmatic execution—a quality that the CurifyLabs team clearly embodies.

Investment Director Joni Karsikas from Tesi echoed this sentiment, stating, "CurifyLabs represents the type of innovative and globally ambitious firm we seek to support. Their growth trajectory in the U.S. is a testament to the competitive capability of Finnish health technology on an international scale."

As the CEO and Founder of CurifyLabs, Charlotta Topelius shared, "This funding highlights our partners' unwavering belief in our vision. We have established high standards for clinical rigor, product quality, and customer support. This investment gives us the capability to elevate these standards even further."

The funding will further support the ongoing evolution of the CurifyLabs platform and especially its latest product, the PharmaPrinter Aurum, which is engineered to compound medications at speeds up to nine times faster than traditional manual preparation methods. CurifyLabs is proud to maintain ISO 13485 certification and adhere to FDA 503A/503B standards for non-sterile compounding, ensuring that their solutions are both effective and compliant.

Founded in 2021, CurifyLabs is on a mission to redefine how personalized medicines are formulated. By combining advanced technology in software and manufacturing with a commitment to quality, the company aims to partner with pharmacies to deliver patient-specific therapies efficiently and reliably. For anyone curious to learn more about their offerings, further information is available at curifylabs.com.

In conclusion, CurifyLabs not only stands at the forefront of healthcare innovation but is also a beacon of excellence in leveraging technology to personalize medicine, ensuring better health outcomes for all.